CoChat
Sign Up
Cited by 56Cervical Cancer and HPV ResearchReproductive tract infections researchHead and Neck Cancer Studies

Epidemiologic Characterization of Human Papillomavirus Infection in Rural Chaozhou, Eastern Guangdong Province of China

Open access
Chen, Qiang, Xie, Long-Xu, Qing, Zhi-Rong, Li, Lie-Jun, Luo, Zhao-Yun, Lin, Min, Zhang, Shi-Ming, Chen, Wen-Zhou +12 more·2012·PLoS ONE
DOI 10.1371/journal.pone.0032149PMC PMC3286448
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Human papilloma virus (HPV) infection was the main cause of cervical cancer. There were only a few reports and detailed data about epidemiological research of HPV infection in rural population of China. MATERIALS AND METHODS: The cervical cells of rural Chaozhou women were collected, and multiplex real time PCR was firstly performed to detect high-risk HPV (HR-HPV) infection, which could detect 13 types of HR-HPV (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68). Then, HPV-positive samples were typed by HPV GenoArray test. RESULTS: HR-HPV DNA was detected by multiplex real time-PCR in 3830 of 48559 cases (7.89%). There was a peak incidence in age of 55-60 years group, and a lower incidence in who lived in plain group compared with suburban, mountain and seashore group. 3380 cases of HPV positive sample were genotyped, 11.01% (372/3380) cases could not be classified, among the typed 3008 cases, 101 cases were identified without HR-HPV type infection, 2907 cases were infected with one HR-HPV type at least, the 6 most common HR-HPV types in descending order of infection, were type 52 (33.4%, 16 (20.95%), 58 (15.93%), 33 (9.94%), 68 (9.22%) and 18 (8.36%). The combined prevalence of HPV types 16 and 18 accounted for 28.52% of total infection. However, type 52 plus 58 presented 48.23% of total infection. 2209/2907 cases were infected with a single HPV type and 698/2907 cases were infected with multiple types, and multiple infection constituent ratio increased with age, with a peak incidence in age 55-60 years group. CONCLUSIONS: Our findings showed low prevalence of HPV vaccine types (16 and 18) and relatively high prevalence of HPV-52 and -58, support the hypothesis that the second-generation HPV vaccines including HPV-52 and -58 may offer higher protection for women in rural Guangdong Province.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0032149

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The pattern of multiple infections in women without cancer corroborates with previous studies.

    “In women without cancer multiple infections were most frequently observed in the age group 36–45 years and lowest in >55 years age group which corroborates with previous studies [25, 29].”

    From HPV Genotypes distribution in Indian women with and without cervical carcinoma: Implication for HPV vaccination program in Odisha, Eastern India (2017) · cites this paper as [25]

    The Discussion reports the opposite age pattern in the rural Chaozhou sample: women aged 55–60 had the highest multiple-infection prevalence, which increased with age. The Results (Figure 5C) also describe an increasing multiple-infection ratio with age. Our copy does not present this finding specifically for women without cancer; page numbers are not available in the supplied passages. (LLM, conf=0.88)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

  • In the Chinese population, HPV 16 is the most predominant followed by HPV 52 rather than 18.

    “However, in the Chinese population, HPV 16 is the most predominant followed by HPV 52 rather than 18 [25].”

    From HPV Genotypes distribution in Indian women with and without cervical carcinoma: Implication for HPV vaccination program in Odisha, Eastern India (2017) · cites this paper as [25]

    The Results (Specific Prevalence of HR-HPV Types, Table 3) rank HPV-52 first at 33.40%, HPV-16 second at 20.95%, and HPV-18 at 8.36% in the study population. The Discussion likewise explicitly says HPV-52, rather than HPV-16, was the most commonly identified type in this rural Chaozhou population. The claim reverses the top two types and generalizes a regional finding to the Chinese population. (LLM, conf=0.90)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 28

  1. [1]Munoz N Bosch FX de Sanjose S Herrero R Castellsagué X 2003 Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 518 527 12571259
  2. [2]Trottier H Burchell AN 2009 Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 12 291 307 19684442
  3. [3]Bouvard V Baan R Straif K Grosse Y Secretan B 2009 A review of human carcinogens–Part B: biological agents. Lancet Oncol 10 321 322 19350698
  4. [4]Yoshikawa H 2009 Progress and challenges on HPV vaccination. Uirusu 59 243 248 20218332
  5. [5]Garland SM Hernandez-Avila M Wheeler CM Perez G Harper DM 2007 Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 1928 1943 17494926
  6. [6]Kjaer SK Sigurdsson K Iversen OE Hernandez-Avila M Wheeler CM 2009 A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa) 2 868 878 19789295
  7. [7]Munoz N Manalastas R Jr Pitisuttithum P Tresukosol D Monsonego J 2009: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 373 1949 1957 19493565
  8. [8]Goldie SJ O'Shea M Campos NG Diaz M Sweet S 2008 Health and economic outcomes of HPV 16, 18 vaccination in 72 GAVI-eligible countries. Vaccine 26 4080 4093 18550229
  9. [9]Herrero R 2009 Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 199 919 922 19236278
  10. [10]Clifford GM Gallus S Herrero R Munoz N Snijders PJ 2005 Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 991 998 16168781
  11. [11]Klintschar M Neuhuber F 2000 Evaluation of an alkaline lysis method for the extraction of DNA from whole blood and forensic stains for STR analysis. J Forensic Sci 45 669 673 10855975
  12. [12]Lin M Yang LY Li LJ Wu JR Peng YP 2008 Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. Aust N Z J Obstet Gynaecol 48 189 194 18366494
  13. [13]1989 The 1988 Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses. Developed and approved at a National Cancer Institute Workshop, Bethesda, Maryland, U.S.A., December 12–13, 1988. J Reprod Med 34 779 785 2677354
  14. [17]Jin Q Shen K Li H Zhou XR Huang HF 2009 Prevalence of human papillomavirus infection in women in Tibet Autonomous Region of China. Zhonghua Fu Chan Ke Za Zhi 44 898 902 20193415
  15. [18]Yip YC Ngai KL Vong HT Tzang LC Ji S 2010 Prevalence and genotype distribution of cervical human papillomavirus infection in Macao. J Med Virol 82 1724 1729 20827770
  16. [19]Li C Wu M Wang J Zhang S Zhu L 2010 A population-based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing, People's Republic of China. Cancer Epidemiol Biomarkers Prev 19 2655 2664 20719907
  17. [20]Ye J Cheng X Chen X Ye F Lü W 2010 Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virol J 7 66 20307327 PMC2857835
  18. [21]Wu RF Liu ZH Zhou QZ Wulan N Wang Q 2010 Prevalence of high-risk human papillomavirus and incidence of cervical intraepithelial neoplasia in female populations in Shenzhen, Guangdong Province. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 32 90 95 20236596
  19. [22]de Sanjose S Diaz M Castellsague X Clifford G Bruni L 2007 Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a metaanalysis. Lancet Infect Dis 7 453 459 17597569
  20. [23]Dai M Bao YP Li N Clifford GM Vaccarella S 2006 Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer 95 96 101 16773069 PMC2360486
  21. [24]Li LK Dai M Clifford GM Yao WQ Arslan A 2006 Human papillomavirus infection in Shenyang City, People's Republic of China: A population-based study. Br J Cancer 95 1593 1597 17088908 PMC2360733
  22. [25]Liu SS Chan KY Leung RC Chan KK Tam KF 2011 Prevalence and Risk Factors of Human Papillomavirus (HPV) Infection in Southern Chinese Women - A Population-Based Study. PLoS One 6 5 e19244 21559276 PMC3086888
  23. [26]Inoue M Sakaguchi J Sasagawa T Tango M 2006 The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 16 1007 1013 16803477
  24. [27]Hildesheim A Wang SS 2002 Host and viral genetics and risk of cervical cancer: a review. Virus Res 89 229 240 12445662
  25. [28]Paolini F Rollo F Brandi R Benevolo M Mariani L 2011 High risk human papillomavirus genotyping in clinical samples: evaluation of different commercial tests. Int J Immunopathol Pharmacol 24 127 138 21496395
  26. [29]Liu SS Leung RC Chan KK Cheung AN Ngan HY 2010 Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay. J Clin Microbiol 48 758 764 20042614 PMC2832468
  27. [30]Bosch FX de Sanjose S 2007 The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 23 213 227 17627057 PMC3850867
  28. [31]Kjaer SK Chackerian B Brule van den AJ Svare EI Paull G 2001 High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 10 101 106 11219765

Cited by

Sorted by citations

Authors
Chen, Q., Xie, L.-X., Qing, Z.-R., Li, L.-J., Luo, Z.-Y., Lin, M., Zhang, S.-M., Chen, W.-Z., Lin, B.-Z., Lin, Q.-L., Li, H., Chen, W.-P., Zheng, P.-Y., Mao, L.-Z., Chen, C.-Y., Yang, C., Zhan, Y.-Z., Liu, X.-Z., Zheng, J.-K., & Yang, L.-Y.
Affiliations
  • Jilin University (CN)
  • Chaozhou Central Hospital (CN)
  • Guangdong Province Women and Children Hospital (CN)
Corresponding author
Yang, Li-Ye
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2012-02-24
Volume
7
Issue
2
Pages
e32149
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0032149
PMC
PMC3286448
OpenAlex
W1998870983
Cited by
56
References
1
Citations by year
2025: 2 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 6 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 10 · 2013: 7 · 2012: 2
FWCI
5.99
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Peking University First Hospital
  • Chinese Center for Disease Control and Prevention
  • Peking University
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
human papillomavirus, high-risk HPV, HPV prevalence, rural women, cervical cancer, HPV genotyping, HPV16, HPV 18, HPV52, HPV58, multiple HPV infection, age distribution, Chaozhou, urban-rural differences, HPV 31, HPV 33, HPV68, HPV35, HPV39, HPV 56, HPV 59, HPV51
MeSH terms
Adult, Uterine Cervical Neoplasms, China, Cross-Sectional Studies, DNA, Viral, Female, Humans, Middle Aged, Rural Population, Genetic Variation, Prevalence, Polymerase Chain Reaction, Treatment Outcome, Sequence Analysis, DNA, Papillomaviridae, Papillomavirus Infections, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review